US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Circio Holding ASA - Final results of the warrant exercise

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 19 December 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 18 December 2024, regarding the preliminary results for the exercise period for the 13,864,852 warrants (the "Warrants"),

Circio raises NOK 10.7 million in upsized offering from new and existing shareholders

· Circio has raised a total of approx. NOK 10.7 million in new capital from the exercise of warrants and a private placement carried out on 18 December 2024 · Applications for allocation of available warrants were 3 times oversubscribed · The shareholder base has been strengthened by the addition of two new experienced biotech investorsOslo, Norway 18 December 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that it has secured approx. NOK 10.7 million in financing to

Circio Holding ASA - Preliminary results of the warrant exercise

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 December 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 4 December 2024, regarding the first day of the exercise period for the 13,864,852 warrants (the "Warrants") issued in

Circio Holding ASA - Allocation of Available Warrants and Private Placement completed

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 December 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 13 December 2024, regarding the invitation to receive available warrants and subscribe for new shares in the Company (

Circio Holding ASA – Last day of exercise period for warrants issued in July 2024

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, Norway 18 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for warrants from 4 December 2024 to 16:30 hours (CET) om 18

Circio Holding ASA – Transfer of rights to warrants from primary insiders

Oslo, Norway 17 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). A total of 13,864,852 warrants (the “Warrants”) were issued and registered with the Norwegian Register of Business Enterprises on 26 July 2024 in relation to the rights issue completed in July 2024. Each Warrant gives the holder a right to subscribe for one new share in the Company at an exercise price per share of NOK 0.60 during the exercise period

Circio Holding ASA – Exercise of Warrants by primary insiders on the Board of Directors

Oslo, Norway 17 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). A total of 176,780 Warrants have been exercised by board members of Circio, for the allocation of 176,780 New Shares in the Company at a price per New Share of NOK 0.60.   Sølen AS, a company owned by Thomas Falck, board member of Circio, has on 13 December 2024 exercised a total of 93,600 Warrants, for the allocation of 93,600 New Shares in the

Circio Holding ASA – Invitation to receive Warrants and subscribe for new shares

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, Norway, 15 December 2024: Reference is made to the rights issue by Circio Holding ASA (the "Company") completed in July 2024 (the "Rights Issue"). Due to substantial interest from existing shareholders and new investors for the ongoing

Circio Holding ASA – Exercise of Warrants by primary insider

Oslo, Norway 13 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). Victor Levitsky, Chief Scientific Officer of Circio, has on 12 December 2024 exercised a total of 46,800 Warrants, for the allocation of 46,800 New Shares in the Company at a price per New Share of NOK 0.60. This represents all of the Warrants issued to Victor Levitsky in connection with the Rights Issue completed in July 2024. A total of 13,864,

Circio Holding ASA – Exercise of Warrants by primary insider

Oslo, Norway 11 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). Thomas Birkballe Hansen, Chief Technology Officer of Circio, has on 10 December 2024 exercised a total of 46,800 Warrants, for the allocation of 46,800 New Shares in the Company at a price per New Share of NOK 0.60. This represents all of the Warrants issued to Thomas Birkballe Hansen in connection with the Rights Issue completed in July 2024. A

Circio Holding ASA – Exercise of Warrants by primary insider

Oslo, Norway 10 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). Ola Melin, Chief Operating Officer of Circio, has on 9 December 2024 exercised a total of 46,800 Warrants, for the allocation of 46,800 New Shares in the Company at a price per New Share of NOK 0.60. This represents all of the Warrants issued to Ola Melin in connection with the Rights Issue completed in July 2024. A total of 13,864,852 warrants (

Circio Holding ASA – Exercise of Warrants by primary insider

Oslo, Norway 9 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). BioPharma Drug Licensing Group SL ("BioPharma"), a company owned by Lubor Gaal, the CFO of Circio, has on 6 December 2024 exercised a total of 93,600 Warrants, for the allocation of 93,600 New Shares in the Company at a price per New Share of NOK 0.60. This represents all of the Warrants issued to BioPharma in connection with the Rights Issue

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 5,000,000 which, pursuant to the bond terms, are convertible into 6,884,207 new shares in the Company at a conversion price of NOK 0.7263. The Company's share capital will accordingly be increased by NOK 4,130,524.20 by the issuance of 6,884,207 new

Circio Holding ASA – Exercise of Warrants by primary insider CEO Erik D Wiklund

Oslo, Norway 5 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). Erik Digman Wiklund, CEO of Circio, has on 5 December 2024 exercised a total of 140,400 Warrants, for the allocation of 140,400 New Shares in the Company at a price per New Share of NOK 0.60. This represents all of the Warrants issued to Erik Digman Wiklund in connection with the Rights Issue completed in July 2024. A total of 13,864,852 warrants (

Circio announces novel circVec 3.0 generation and circular mRNA half-life up to 75 times longer than linear mRNA in vivo

· Novel circVec 3.0 design feature achieves 27- and 4-fold improvement vs. circVec 1.1 and 2.1 generation, respectively · circVec circular mRNA shows up to 75 times longer half-life than conventional linear mRNA in vivo · Muscle-specific circVec 2.0-AAV vectors validated by systemic delivery in vivo · The results will be discussed in a live webcast 

Circio Holding ASA – Funding requested under financing commitment from Atlas

Oslo, Norway 4 December 2024: Reference is made to Circio Holding ASA's (the "Company") stock exchange announcement on 29 May 2024, regarding the financing commitment provided by Atlas to fund the Company´s operations until the end of June 2025 (the “Financing Commitment”). The Company has by a notice of exercise under the Agreement and the Financing Commitment requested Atlas to subscribe and pay for one additional tranche of convertible bonds, consisting of 8 convertible bonds with an aggregate principal amount equal to NOK 4,000,000. Atlas will be allocated these bonds under the terms

Circio Holding ASA - Commencement of exercise period for warrants issued in July 2024

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, Norway 4 December 2024: Reference is made to the rights issue by Circio Holding ASA completed in July 2024 (the "Rights Issue"). The subscribers in the rights issue were allocated 7,242,992 warrants (Nw.: frittstående tegningsrett). In

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 2 December 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 27 November 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 27,264,865.20 divided into 45,441,442 shares, each with a nominal value of NOK 0.60.

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are convertible into 3,468,047 new shares in the Company at a conversion price of NOK 0.72087. The Company's share capital will accordingly be increased by NOK 2,080,828.20 by the issuance of 3,468,047 new

Circio announces circVec LNP-delivery collaboration with Certest progressing to in vivo testing

· Certest Biotec, S.L. and Circio are collaborating to create and test circVec DNA-LNP formulations for potential therapeutic applications · Certest´s proprietary ionizable lipids and their optimized LNP formulations have shown impressive delivery specificity to several tissues of interest to Circio, including lung, liver and spleen · Technical formulation and in vitro analysis of circVec-LNP formulations by Certest have been successful, and the collaboration will now progress to in vivo delivery testingOslo, Norway 19 November 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 14 November 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 12 November 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 25,184,037.00 divided into 41,973,395 shares, each with a nominal value of NOK 0.60.

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 5,000,000 which, pursuant to the bond terms, are convertible into 8,287,750 new shares in the Company at a conversion price of NOK 0.6033. The Company's share capital will accordingly be increased by NOK 4,972,650.00 by the issuance of 8,287,750 new

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 5 November 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 1 November 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 20,211,387.00 divided into 33,685,645 shares, each with a nominal value of NOK 0.60.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe